deltatrials

Stage iiia breast cancer ajcc v7 Trials in Jacksonville, United States

Conditions / Stage iiia breast cancer ajcc v7 / Jacksonville, United States

Research into Stage iiia breast cancer ajcc v7 spans multiple therapeutic approaches and trial phases.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT02912312 Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer ACTIVE_NOT_RECRUITING PHASE2
NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer ACTIVE_NOT_RECRUITING PHASE2
NCT02311933 Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT02003209 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer COMPLETED PHASE3
NCT02311933 Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT04197687 TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery UNKNOWN PHASE2
NCT01275677 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer COMPLETED PHASE3
NCT00005970 Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer COMPLETED PHASE3
NCT02311933 Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT03281902 Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy ACTIVE_NOT_RECRUITING

Related Pages